Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | SGN35-027: Brentuximab vedotin with nivolumab, doxorubicin, and dacarbazine in HL

Ian Flinn • 9 Dec 2021
ASH 2021
Hodgkin Lymphoma Lymphoma Antibodies Brentuximab vedotin Dacarbazine Doxorubicin Nivolumab
SGN35-027

Existing trials have shown brentuximab vedotin, a CD30-directed antibody-drug conjugate (ADC), with vinblastine, as well as nivolumab monotherapy to have good efficacy and safety profiles in patients with Hodgkin lymphoma. Ian Flinn, MD, PhD, Tennessee Oncology, Nashville, TN, provides an overview of the trial design and rationale of the open-label, Phase II SGN35-027 trial (NCT03646123), which will investigate brentuximab vedotin in combination with nivolumab, doxorubicin, and dacarbazine in patients with newly diagnosed patients with early-stage Hodgkin lymphoma. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

More from Ian Flinn

0:57
Unanswered questions in frontline CLL treatment
Ian Flinn • 9 Dec 2021
1:55
Umbralisib and ublituximab in patients with CLL and comorbidities
Ian Flinn • 9 Dec 2021
2:48
Debulking strategies in CLL before venetoclax therapy
Ian Flinn • 9 Dec 2021
3:43
Safety and efficacy of YTB323, a CAR T-cell therapy, in r/r DLBCL
Ian Flinn • 9 Dec 2021

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals